Back to search
FDAFDA · Food and drugs·Recall number D-063-2013

Reumofan Plus Tablets, 30-count bottle per Box, (remaining label information in Spanish)

Published December 5, 2012 · Recall initiated: August 27, 2012

Summary

FDA records drug Class I recall D-063-2013, published December 5, 2012 and initiated August 27, 2012. Recalling firm: Samantha Lynn, Inc; Status: Terminated; Reported quantity: 25,888 Boxes; Lot: all lots within expiry through 2016. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed without an approved NDA/ANDA: Samantha Lynn Inc. is recalling Reumofan Plus Tablets because it contains undeclared drug ingredients making it an unapproved drug.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Samantha Lynn, Inc
Distributor
Nationwide and Canada, Australia, Germany, Brazil, Austria, United Kingdom, India, Chile, Switzerland, Thailand, Japan
Lot
all lots within expiry through 2016
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Reumofan Plus Tablets, 30-count bottle per Box, (remaining label information in Spanish) recalled?

Yes. FDA published recall D-063-2013 on December 5, 2012. Reported hazard: Marketed without an approved NDA/ANDA: Samantha Lynn Inc. is recalling Reumofan Plus Tablets because it contains undeclared drug ingredients making it an unapproved drug.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release